Jeffrey N Weiss1, Steven Levy2. 1. Coral Ridge Medical Center, 821 Coral Ridge Drive, Coral Springs, FL 33065, USA. 2. MD Stem Cells, 3 Sylvan Road South, Westport, CT 06880, USA.
Abstract
Background: Stargardt Disease is the most common inherited macular degeneration, typically resulting in progressive central vision loss and legal blindness at an early age. We report regarding 34 eyes with Stargardt Disease treated in the Stem Cell Ophthalmology Treatment Study (SCOTS and SCOTS2). Methods: Autologous bone marrow was processed, separating the stem cell fraction which was provided Arms using retrobulbar, subtenons, intravitreal or subretinal and intravenous. The follow-up period was one year. Results: Of the 34 treated eyes, 21 (61.8%) improved, 8 (23.5%) remained stable, and 5 (14.7%) showed continued progression of their disease. Results were statistically significant with p = 0.0004. The average central vision improvement following treatment was 17.96% (95%CI, 16.39-19.53%) and ranged up to 80.5%. Of 17 patients treated, 13 (76.5%) showed visual acuity improvement in one or both eyes, 3 patients (17.6%) showed no net loss, and 1 worsened as a consequence of disease progression; 94.1% of patients had improved vision or remained stable. There were no adverse events. Conclusions: Patients with Stargardt Disease may potentially benefit from autologous bone marrow-derived stem cells (BMSC) as provided in SCOTS. Improvement or stabilization of vision was found to occur for the vast majority of reported patients and findings were highly statistically significant.
Background: Stargardt Disease is the most common inherited macular degeneration, typically resulting in progressive central vision loss and legal blindness at an early age. We report regarding 34 eyes with Stargardt Disease treated in the Stem Cell Ophthalmology Treatment Study (SCOTS and SCOTS2). Methods: Autologous bone marrow was processed, separating the stem cell fraction which was provided Arms using retrobulbar, subtenons, intravitreal or subretinal and intravenous. The follow-up period was one year. Results: Of the 34 treated eyes, 21 (61.8%) improved, 8 (23.5%) remained stable, and 5 (14.7%) showed continued progression of their disease. Results were statistically significant with p = 0.0004. The average central vision improvement following treatment was 17.96% (95%CI, 16.39-19.53%) and ranged up to 80.5%. Of 17 patients treated, 13 (76.5%) showed visual acuity improvement in one or both eyes, 3 patients (17.6%) showed no net loss, and 1 worsened as a consequence of disease progression; 94.1% of patients had improved vision or remained stable. There were no adverse events. Conclusions: Patients with Stargardt Disease may potentially benefit from autologous bone marrow-derived stem cells (BMSC) as provided in SCOTS. Improvement or stabilization of vision was found to occur for the vast majority of reported patients and findings were highly statistically significant.
Authors: Steven D Schwartz; Carl D Regillo; Byron L Lam; Dean Eliott; Philip J Rosenfeld; Ninel Z Gregori; Jean-Pierre Hubschman; Janet L Davis; Gad Heilwell; Marc Spirn; Joseph Maguire; Roger Gay; Jane Bateman; Rosaleen M Ostrick; Debra Morris; Matthew Vincent; Eddy Anglade; Lucian V Del Priore; Robert Lanza Journal: Lancet Date: 2014-10-15 Impact factor: 79.321
Authors: Rupert W Strauss; Beatriz Muñoz; Alexander Ho; Anamika Jha; Michel Michaelides; Artur V Cideciyan; Isabelle Audo; David G Birch; Amir H Hariri; Muneeswar G Nittala; SriniVas Sadda; Sheila West; Hendrik P N Scholl Journal: JAMA Ophthalmol Date: 2017-11-01 Impact factor: 7.389
Authors: Kaoru Fujinami; Jana Zernant; Ravinder K Chana; Genevieve A Wright; Kazushige Tsunoda; Yoko Ozawa; Kazuo Tsubota; Anthony G Robson; Graham E Holder; Rando Allikmets; Michel Michaelides; Anthony T Moore Journal: Ophthalmology Date: 2014-10-12 Impact factor: 12.079
Authors: Martina Pesaresi; Sergi A Bonilla-Pons; Giacoma Simonte; Daniela Sanges; Umberto Di Vicino; Maria Pia Cosma Journal: EBioMedicine Date: 2018-02-28 Impact factor: 8.143
Authors: Diego Garcia-Ayuso; Johnny Di Pierdomenico; David García-Bernal; Manuel Vidal-Sanz; María P Villegas-Pérez Journal: Neural Regen Res Date: 2022-09 Impact factor: 5.135